6,541 Shares of Moderna, Inc. $MRNA Purchased by Caldwell Trust Co

Key Points

• Caldwell Trust acquired 6,541 Moderna shares in the third quarter, valued at about $1.26 million. Institutional investors collectively own 75.33% of the company’s stock.
• Moderna shares opened at $241.46, near their 12-month high of $261. Analysts’ consensus rating was Hold, with an average price target of $107.10.
• Company executives reported stock sales, including President Stephen Hoge’s sale of 39,145 shares under a pre-arranged trading plan. Insiders sold 197,251 shares worth about $33.9 million over the preceding three months.

Caldwell Trust Co acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,541 shares of the company's stock, valued at approximately $1,260,000.

A number of other institutional investors have also made changes to their positions in the stock. BlackRock Inc. bought a new stake in Moderna during the second quarter worth approximately $2,142,877,000. Theleme Partners LLP acquired a new position in Moderna during the second quarter valued at approximately $564,272,000. Merck & Co. Inc. bought a new position in shares of Moderna in the second quarter valued at approximately $161,642,545. Bamco Inc. NY bought a new position in shares of Moderna in the second quarter valued at approximately $139,317,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Moderna in the second quarter valued at approximately $119,168,000. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $241.46 on Friday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The business's 50 day moving average is $189.62 and its two-hundred day moving average is $90.46. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $261.00.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Piper Sandler restated an "overweight" rating and issued a $230.00 price objective (up from $167.00) on shares of Moderna in a research note on Monday, October 26th. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $130.00 target price on shares of Moderna in a research note on Wednesday, August 19th. The Goldman Sachs Group raised their target price on shares of Moderna from $120.00 to $137.00 and gave the company a "neutral" rating in a research note on Thursday, October 15th. Wolfe Research upgraded shares of Moderna from an "underperform" rating to a "peer perform" rating in a report on Tuesday, August 25th. Finally, Jefferies Financial Group reissued a "hold" rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $107.10.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Health Canada authorized Moderna’s mRNA seasonal influenza vaccine and its combined influenza/COVID-19 vaccine for adults 50 and older, making Canada the first country to authorize both products. The approvals expand potential commercial opportunities, though sales and uptake remain to be seen. Health Canada authorizes Moderna’s vaccines
• Positive Sentiment: Moderna’s investigational multiple-myeloma therapy mRNA-2808 generated four confirmed responses among 11 heavily pretreated patients in early data. The results are preliminary, but helped fuel optimism about the company’s cancer platform; fuller data are scheduled for presentation at a December medical meeting. Early multiple-myeloma data
• Positive Sentiment: The WHO’s technical advisory group recommended advancing Moderna’s Bundibugyo Ebola vaccine candidate to a Phase 2/3 efficacy study in the Democratic Republic of the Congo, a positive development for its pipeline. Ebola vaccine advances toward Phase 2/3
• Neutral Sentiment: Investors are looking to Friday’s earnings report for updates on revenue, cash use, and the company’s ability to fund its pipeline. The results could be an important test after a steep rally. Q3 earnings preview
• Negative Sentiment: U.S. judges pressed Moderna on its defense in a COVID-19 vaccine patent dispute that could involve billions of dollars, raising uncertainty about potential legal exposure. Moderna pressed on patent defense
• Negative Sentiment: Some commentary argues the stock’s valuation has run ahead of near-term revenue prospects, citing ongoing cash burn and commercial hurdles for pipeline products. That risk may weigh more heavily if earnings do not support the rally. Moderna earnings and valuation analysis

Insider Activity

In other news, President Stephen Hoge sold 39,145 shares of the firm's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the sale, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.